Skip to main content
Search
Main content

Prof Paul Matthews

OBE, DPhil, MD, FRCP, FMedSci (He/Him)

Group Leader

Exploring neuronal vulnerability and genetic risk variants in Alzheimer’s progression

Techniques

Bioinformatics, Stem cells / iPSCs, Lipidomics, Advanced spectroscopy, Biophysical techniques, Experimental medicine, Human brain imaging, Single cell / nucleus transcriptomics, Statistical modelling

Biography

Paul is a neurologist with a research focus on neuroinflammatory mechanisms of neurodegeneration in Alzheimer’s disease (AD) and multiple sclerosis.


He read chemistry as an undergraduate in Oxford, completed his DPhil there in the biochemistry laboratory of Prof. Sir George Radda, then obtained an MD and was an intern in medicine at Stanford University with a part-time post-doctoral period in the Department of Pharmacology before moving to the Montreal Neurological Institute (MNI) for a Residency in Neurology. Following this, he spent a further three post-doctoral years in the Genetics Laboratory in Oxford before becoming an Assistant Professor of Neurology and Genetics at McGill University. He returned to Oxford in 1995 as an MRC Clinical Research Reader (later Professor) where he was the founding Director of Oxford’s Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB). From 2005, he became a Vice President in GlaxoSmithKline, holding a variety of senior portfolios, including those for the GSK Clinical Imaging Centre and, later, the Global Imaging Group. He was Chair of the UKRI MRC Neuroscience and Mental Health Board 2020-24.


Paul is a Fellow of the Academy of Medical Sciences, a Fellow by Special Election of St Edmund Hall, Oxford and a Fellow of the Academia Europea. He was made an Officer of the Most Excellent Order of the British Empire (OBE) in 2008 for services to Neuroscience.  

News

Key publications

Alzheimers Res Ther
Published

Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia.

Authors
Aitana Sogorb-Esteve, Johanna Nilsson, Imogen J Swift, Carolin Heller, Martina Bocchetta, Lucy L Russell, Georgia Peakman, Rhian S Convery, John C van Swieten, Harro Seelaar, Barbara Borroni, Daniela Galimberti, Raquel Sanchez-Valle, Robert Laforce, Fermin Moreno, Matthis Synofzik, Caroline Graff, Mario Masellis, Maria Carmela Tartaglia, James B Rowe, Rik Vandenberghe, Elizabeth Finger, Fabrizio Tagliavini, Isabel Santana, Chris R Butler, Simon Ducharme, Alexander Gerhard, Adrian Danek, Johannes Levin, Markus Otto, Sandro Sorbi, Isabelle Le Ber, Florence Pasquier, Johan Gobom, Ann Brinkmalm, Kaj Blennow, Henrik Zetterberg, Jonathan D Rohrer
Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia.
Lancet Neurol
Published

A biological classification of Huntington's disease: the Integrated Staging System.

Authors
Sarah J Tabrizi, Scott Schobel, Emily C Gantman, Alexandra Mansbach, Beth Borowsky, Pavlina Konstantinova, Tiago A Mestre, Jennifer Panagoulias, Christopher A Ross, Maurice Zauderer, Ariana P Mullin, Klaus Romero, Sudhir Sivakumaran, Emily C Turner, Jeffrey D Long, Cristina Sampaio
A biological classification of Huntington's disease: the Integrated Staging System.
Intensive Care Med
Published

Natural history, trajectory, and management of mechanically ventilated COVID-19 patients in the United Kingdom.

Authors
Brijesh V Patel, Shlomi Haar, Rhodri Handslip, Chaiyawan Auepanwiriyakul, Teresa Mei-Ling Lee, Sunil Patel, J Alex Harston, Feargus Hosking-Jervis, Donna Kelly, Barnaby Sanderson, Barbara Borgatta, Kate Tatham, Ingeborg Welters, Luigi Camporota, Anthony C Gordon, Matthieu Komorowski, David Antcliffe, John R Prowle, Zudin Puthucheary, Aldo A Faisal
Natural history, trajectory, and management of mechanically ventilated COVID-19 patients in the United Kingdom.

Matthews Lab

Explore the work of the Matthews Lab focused on neuronal vulnerability and genetic risk variants in the progression of Alzheimer’s disease.